3.56
-0.05(-1.39%)
Currency In USD
| Previous Close | 3.61 |
| Open | 3.7 |
| Day High | 3.73 |
| Day Low | 3.55 |
| 52-Week High | 8.06 |
| 52-Week Low | 3.21 |
| Volume | 3.31M |
| Average Volume | 5.71M |
| Market Cap | 851.75M |
| PE | -15.48 |
| EPS | -0.23 |
| Moving Average 50 Days | 4.13 |
| Moving Average 200 Days | 5.16 |
| Change | -0.05 |
If you invested $1000 in Ardelyx, Inc. (ARDX) 10 years ago, it would be worth $866.18 as of June 21, 2025 at a share price of $3.56. Whereas If you bought $1000 worth of Ardelyx, Inc. (ARDX) shares 5 years ago, it would be worth $2,000 as of June 21, 2025 at a share price of $3.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
GlobeNewswire Inc.
Jun 02, 2025 8:05 PM GMT
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
GlobeNewswire Inc.
May 21, 2025 12:00 PM GMT
WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs,
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
GlobeNewswire Inc.
May 06, 2025 12:01 PM GMT
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distressWALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded